Related Experiment Video
Updated: Jul 14, 2026

An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents
Published on: December 2, 2015
Depression and coronary artery disease
Nancy Frasure-Smith1, François Lespérance
1Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Recherche Psychiatrie, Montréal,Québec, Canada.
Insights
Depression affects up to 20% of cardiac patients, significantly increasing their risk of future heart events. Addressing depression may be a crucial, modifiable cardiac risk factor.
Area of Science:
- Cardiology
- Psychiatry
- Preventive Medicine
Background:
- Major depression and depressive symptoms are prevalent in patients with coronary artery disease (CAD), occurring at rates three times higher than in the general population.
- Approximately 12-20% of hospitalized cardiac patients meet criteria for major depression, with a similar percentage reporting elevated depressive symptoms.
Purpose of the Study:
- To highlight the significant prevalence of depression in patients with CAD.
- To underscore the association between depression and increased risk of subsequent cardiac events.
- To explore potential mechanisms linking depression and CAD and the role of omega-3 fatty acids.
Main Methods:
- Review of studies involving patients recovering from myocardial infarction, unstable angina, coronary bypass surgery, and coronary angioplasty.
- Analysis of epidemiological data linking depression and CAD development.
- Examination of proposed biological mechanisms connecting depression and cardiovascular disease.
Main Results:
- Depression is not a normal response to cardiac disease but a significant risk factor, more than doubling the risk of future cardiac events.
- Depression can precede the clinical diagnosis of CAD by many years, indicating a potential causal or contributory role.
- Proposed mechanisms include autonomic dysregulation, inflammation, endothelial dysfunction, and altered platelet activity, with omega-3 fatty acids implicated in both depression and CAD.
Conclusions:
- Depression is a highly prevalent and serious comorbidity in CAD patients, acting as a modifiable risk factor.
- Further clinical trials investigating the impact of omega-3 supplements on depression in both CAD patients and the general population are warranted.
Abstract:
Studies in patients recovering from myocardial infarction, episodes of unstable angina, coronary bypass surgery and coronary angioplasty, show that between 12 and 20% of hospitalized cardiac patients meet psychiatric criteria for current major depression. A similar percentage report elevated levels of depressive symptoms on paper and pencil self-report measures. These rates of depression are about three times higher than in the general community. On a practical basis this means that about one in three hospitalized CAD patients has some degree of depression. Despite its high prevalence in patients with CAD, depression is not a normal reaction to cardiac disease. Both major depression and elevated depressive symptoms are associated with at least a doubling in risk of subsequent cardiac events, even when standard cardiac risk factors, including left ventricular ejection fraction and number of blocked coronary arteries, are taken into account. In fact, several large, longitudinal community-based studies show that depression precedes the development of clinically evident CAD by many years. There is substantial evidence that depression is a potentially modifiable cardiac risk factor of as much importance as diabetes or lack of exercise. Although the precise mechanisms explaining the link between depression and CAD remain unknown, there is evidence that changes in autonomic regulation, sub-chronic inflammation, endothelial dysfunction, enhanced platelet responsiveness and reduced omega-3 free fatty acid levels may all be involved. Intriguingly, the mechanisms that have been hypothesized to explain the link between depression and CAD prognosis are the same as those suggested to explain the favorable impact of omega-3 supplements in CAD patients. Additional clinical trials to assess the impact of omega-3 supplements on depression are clearly warranted both in CAD patients and in individuals free of heart disease.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
